Trevi Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Trevi Therapeutics, Inc. (TRVI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TRVI insiders buying or selling?
In the last 12 months, Trevi Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 1 sale ($595.8K) — net selling of $595.8K. Since May 2019, Trabud has recorded 76 Form 4 filings for TRVI: 41 buys ($381.4M) and 35 sells ($4.6M).
Source: SEC EDGAR Form 4
Key Statistics (May 2019 – Sep 17, 2026)
Total Form 4 filings
76
SEC EDGAR
Insider filers
27
Insider buys (41)
$381.4M
Insider sells (35)
$4.6M
Insider sentiment
Net buyingNet insider flow of $376.7M in net buying since May 2019, and $595.8K in net selling over the last 12 months.
Recent TRVI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Michael Thomas Heffernan | Director | Sale | 39.5K | $15.09 | $595.8K | SEC ↗ |
| Mar 26, 2025 | Thomas Sciascia | Chief Scientific Officer | Sale | 2.6K | $6.60 | $17.4K | SEC ↗ |
| Mar 25, 2025 | Jennifer L Good | President & CEO | Sale | 5.3K | $6.58 | $34.6K | SEC ↗ |
| Mar 12, 2025 | Farrell Simon | Chief Commercial Officer | Sale | 81.3K | $6.75 | $548.9K | SEC ↗ |
| Sep 9, 2024 | Jennifer L Good | President & CEO | Sale | 6.1K | $3.03 | $18.4K | SEC ↗ |
| Sep 5, 2024 | Jennifer L Good | President & CEO | Sale | 55.1K | $3.09 | $170.2K | SEC ↗ |
| Aug 29, 2024 | David P Meeker | Director | Sale | 4.6K | $2.93 | $13.4K | SEC ↗ |
| Aug 21, 2024 | Thomas Sciascia | Chief Scientific Officer | Sale | 16.5K | $2.96 | $48.9K | SEC ↗ |
| Aug 16, 2024 | Thomas Sciascia | Chief Scientific Officer | Sale | 31.5K | $2.77 | $87.2K | SEC ↗ |
| May 31, 2024 | Thomas Sciascia | Chief Scientific Officer | Sale | 53.4K | $2.55 | $136.1K | SEC ↗ |
| May 24, 2024 | Lisa Delfini | Chief Financial Officer | Sale | 4.3K | $2.64 | $11.5K | SEC ↗ |
| May 22, 2024 | Jennifer L Good | President & CEO | Sale | 25.0K | $2.86 | $71.6K | SEC ↗ |
| May 14, 2024 | Jennifer L Good | President & CEO | Sale | 4.6K | $2.90 | $13.3K | SEC ↗ |
| Oct 12, 2023 | Lisa Delfini | Chief Financial Officer | Sale | 785 | $2.02 | $1.6K | SEC ↗ |
| Sep 13, 2023 | Lisa Delfini | Chief Financial Officer | Sale | 711 | $2.20 | $1.6K | SEC ↗ |
| Aug 14, 2023 | Lisa Delfini | Chief Financial Officer | Sale | 682 | $2.36 | $1.6K | SEC ↗ |
| Jul 12, 2023 | Lisa Delfini | Chief Financial Officer | Sale | 687 | $2.34 | $1.6K | SEC ↗ |
| Jun 14, 2023 | Lisa Delfini | Chief Financial Officer | Sale | 610 | $2.64 | $1.6K | SEC ↗ |
| May 15, 2023 | Lisa Delfini | Chief Financial Officer | Sale | 562 | $2.89 | $1.6K | SEC ↗ |
| Mar 15, 2023 | Lisa Delfini | Chief Financial Officer | Sale | 892 | $1.75 | $1.6K | SEC ↗ |
| Feb 15, 2023 | Lisa Delfini | Chief Financial Officer | Sale | 8.5K | $2.45 | $20.8K | SEC ↗ |
| Jul 6, 2022 | David Bonderman | Other | Sale | 500.0K | $2.89 | $1.4M | SEC ↗ |
| Jul 1, 2022 | David Bonderman | 10% Owner | Sale | 476.0K | $2.77 | $1.3M | SEC ↗ |
| May 4, 2022 | David Bonderman | 10% Owner | Sale | 600 | $2.70 | $1.6K | SEC ↗ |
| May 2, 2022 | David Bonderman | 10% Owner | Sale | 23.4K | $2.75 | $64.5K | SEC ↗ |
Showing the 25 most recent of 76 Form 4 filings for Trevi Therapeutics, Inc..
Most active TRVI insiders
- Lisa Delfini9 filings
- Jennifer L Good6 filings
- Ali Behbahani4 filings
- Anthony A. Florence Jr.4 filings
- Carmen Chang4 filings
Ask anything about TRVI insider activity
Use Trabud's AI agent to query Trevi Therapeutics, Inc.'s Form 4 history in plain English — "Show me TRVI CEO purchases this year" or compare it against any other ticker.
Open the AI agentTRVI insider trading FAQ
Are Trevi Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Trevi Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 1 sale ($595.8K) — net selling of $595.8K. Since May 2019, Trabud has recorded 76 Form 4 filings for TRVI: 41 buys ($381.4M) and 35 sells ($4.6M). Over the full record that is net buying of $376.7M.
How many insiders trade TRVI stock?
27 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Trevi Therapeutics, Inc.. The most recent filing was accepted on Sep 17, 2026.
Where does Trabud get TRVI insider trading data?
All TRVI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.